Drug Profile
Taladegib - Endeavor BioMedicines
Alternative Names: ENV 101; ENV-IPF-101; ENV-ONC-101; LY-2940680Latest Information Update: 31 Jan 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Endeavor BioMedicines; Ignyta
- Class Antifibrotics; Antineoplastics; Benzamides; Fluorobenzenes; Phthalazines; Piperidines; Pyrazoles; Small molecules
- Mechanism of Action SMO protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cancer; Idiopathic pulmonary fibrosis; Solid tumours
- Discontinued Adenocarcinoma; Basal cell cancer; Ovarian cancer; Small cell lung cancer
Most Recent Events
- 24 Jan 2024 Endeavor BioMedicines completes phase II trials for Idiopathic pulmonary fibrosis in Mexico, Malaysia, South Korea, Canada and Australia (PO) (NCT04968574)
- 06 Sep 2023 Endeavor BioMedicines completes enrolment in its Phase-II clinical trials for Idiopathic pulmonary fibrosis in Mexico, Malaysia, South Korea, Canada and Australia (PO) (NCT04968574)
- 11 Jun 2023 Endeavor Biomedicines completes a phase I trial in Idiopathic Pulmonary Fibrosis (In healthy volunteers) in Australia (NCT05817240)